These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

741 related items for PubMed ID: 18838885

  • 1. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
    Rose PG, Rodriguez M, Walker J, Greer B, Fusco N, McGuire W.
    Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
    Rose PG, Greer BE, Horowitz IR, Markman M, Fusco N.
    Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
    [Abstract] [Full Text] [Related]

  • 5. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin.
    Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A.
    Cancer Invest; 2005 Jan; 23(8):665-70. PubMed ID: 16377584
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
    Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6080-5. PubMed ID: 15447993
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
    Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, Kavanagh J, Vermorken JB, Meng L, Jones M, Brown G, Kaye S, ASSIST-1 Study Group.
    Eur J Cancer; 2009 Sep 15; 45(13):2324-32. PubMed ID: 19515553
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.
    Gynecol Oncol; 2008 Dec 15; 111(3):467-73. PubMed ID: 18834619
    [Abstract] [Full Text] [Related]

  • 16. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
    Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ.
    Gynecol Oncol; 2006 Oct 15; 103(1):212-8. PubMed ID: 16677696
    [Abstract] [Full Text] [Related]

  • 17. Role of pegylated liposomal doxorubicin in ovarian cancer.
    Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG.
    Gynecol Oncol; 2005 Jan 15; 96(1):10-8. PubMed ID: 15589573
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
    Elkas JC, Winter WE, Chernofsky MR, Sunde J, Bidus MA, Bernstein S, Rose GS.
    Gynecol Oncol; 2007 Feb 15; 104(2):422-7. PubMed ID: 16996118
    [Abstract] [Full Text] [Related]

  • 19. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
    Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, Riva N, De Rosa V, Gallo C, Perrone F, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group.
    Br J Cancer; 2007 Jun 04; 96(11):1639-43. PubMed ID: 17486128
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G, Gorchev G, Sehouli J, Wimberger P, Stähle A, Hanker L, Hilpert F, Sindermann H, Gründker C, Harter P.
    Gynecol Oncol; 2014 Jun 04; 133(3):427-32. PubMed ID: 24713545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.